Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)
Keyword(s):
Phase 2
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 3557-3557
◽